The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19

Shih-Lung Cheng,1,2 Ping-Huai Wang,1 Cheng-Yu Chang,1 Hsu-Hui Wang,1 Chung-Jen Wang,1 Kuan-Ming Chiu2,3 1Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan; 2The Graduate Institute of Medicine, Yuan-Ze University, Taoyuan City, Taiwan; 3Division of Cardiovas...

Full description

Bibliographic Details
Main Authors:	Cheng SL, Wang PH, Chang CY, Wang HH, Wang CJ, Chiu KM
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-01-01
Series:	Drug Design, Development and Therapy
Subjects:	molnupiravir covid-19 healthcare facility clinical benefit hospitalization comorbidity
Online Access:	https://www.dovepress.com/the-benefits-of-molnupiravir-treatment-in-healthcare-facilities-patien-peer-reviewed-fulltext-article-DDDT

Similar Items

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
by: Michela Pontolillo, et al.
Published: (2022-09-01)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
by: Divya Teli, et al.
Published: (2023-02-01)

Safety and Effectiveness of Molnupiravir in Covid-19 Treatment: A Rapid Review
by: Mohammadreza Mobinizadeh, et al.
Published: (2022-10-01)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
by: Wen Wen, et al.
Published: (2022-12-01)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
by: Ching-Chi Lee, et al.
Published: (2021-10-01)

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo
by: Yuexiang Li, et al.
Published: (2022-05-01)

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
by: Zi-Xin Huang, et al.
Published: (2023-06-01)

Molnupiravir; an effective drug in treating COVID-19?
by: Alireza Pouramini, et al.
Published: (2022-01-01)

Can Tremor Be a Rare Side Effect Related to Molnupiravir?
by: Sinan MERMER, et al.
Published: (2022-11-01)

Computational Analysis of Molnupiravir
by: Artem V. Sharov, et al.
Published: (2022-01-01)

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
by: Ashour NA, et al.
Published: (2022-03-01)

Molnupiravir in Combination with Remdesivir for Severe COVID-19 Patients Admitted to Hospital: a Case Series
by: Seyed Mohammad Reza Hashemian, et al.
Published: (2022-04-01)

Efficacy and safety of molnupiravir in adult outpatients with COVID-19
by: Natalia Y. Pshenichnaya, et al.
Published: (2023-06-01)

Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
by: Greta Santi Laurini, et al.
Published: (2022-12-01)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
by: Yuan Bai, et al.
Published: (2022-04-01)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
by: Rongrong Zou, et al.
Published: (2022-06-01)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
by: Clara Weil, et al.
Published: (2023-08-01)

Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection
by: Hikari Mizutani, et al.
Published: (2022-01-01)

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
by: Yoshikazu Mutoh, et al.
Published: (2023-03-01)

Molnupiravir: From Hope to Epic Fail?
by: Daniele Focosi
Published: (2022-11-01)

Why Molnupiravir Fails in Hospitalized Patients
by: Ashley N. Brown, et al.
Published: (2022-12-01)

Full factorial design assisted RP-UHPLC method development and study of stressed degradation of molnupiravir
by: Omar Faruk, et al.
Published: (2024-01-01)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
by: Ashley Jia Wen Yip, et al.
Published: (2022-06-01)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
by: Éva Bakos, et al.
Published: (2023-07-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
by: Ivan Gentile, et al.
Published: (2022-10-01)

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
by: Matthew G. Johnson, et al.
Published: (2024-03-01)

Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
by: Masahiro Kimata, et al.
Published: (2023-03-01)

Molnupiravir and Its Antiviral Activity Against COVID-19
by: Lili Tian, et al.
Published: (2022-04-01)

Siting of Healthcare Care Facilities Based on the Purpose of Their Operation, Demographic Changes, Environmental Characteristics, and the Impact on Public Health
by: Marko Jausovec, et al.
Published: (2021-12-01)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
by: Henrik Berg Rasmussen, et al.
Published: (2023-10-01)

Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience
by: Kinga Czarnecka, et al.
Published: (2022-10-01)

Gardens in healthcare facilities : uses, therapeutic benefits, and design recommendations /
by: 234149 Marcus, Clare Cooper, et al.
Published: (1995)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand
by: Nicolas Salvadori, et al.
Published: (2024-06-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan
by: Shohei Shinozaki, et al.
Published: (2024-01-01)

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
by: Julie M. Strizki, et al.
Published: (2023-11-01)

Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression
by: Antonio Vena, et al.
Published: (2022-07-01)

Accessible art in healthcare facilities: exploring perspectives of healthcare art for visually impaired people
by: Daryia Palityka, et al.
Published: (2023-10-01)